Penwest Halts Beta Blocker Development Following "Not Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will halt development efforts for PW2101 due to FDA's concerns outlined in a "not approvable" letter and because of the limited commercial window for the product.